# Merck & Co. (MSD)

Source: https://onco.cc/companies/merck/  
OnCo record `merck` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.

## Summary

Pembrolizumab anchors >40 indications. Post-2028 patent-cliff strategy: sacituzumab tirumotecan (Kelun licence, >10 phase 3 trials), ifinatamab/patritumab/raludotatug deruxtecan (Daiichi Sankyo alliance, up to $22B), intismeran autogene (Moderna), zilovertamab vedotin, belzutifan, and a PD-1×VEGF bispecific (LaNova).

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Rahway, NJ
- Type: pharma
- Website: https://www.merck.com
- Ticker: MRK

## Sources

- Official website: https://www.merck.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Aprepitant (and fosaprepitant)](https://onco.cc/drugs/aprepitant/), [Belzutifan](https://onco.cc/drugs/belzutifan/), [Bomedemstat](https://onco.cc/drugs/bomedemstat/), [Boserolimab](https://onco.cc/drugs/boserolimab/), [Calderasib](https://onco.cc/drugs/calderasib/), [Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Epacadostat](https://onco.cc/drugs/epacadostat/), [Favezelimab](https://onco.cc/drugs/favezelimab/), [Flutamide](https://onco.cc/drugs/flutamide/), [HPV quadrivalent vaccine (types 6, 11, 16 and 18)](https://onco.cc/drugs/hpv-quadrivalent-vaccine/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/), [Interferon alfa-2a/2b](https://onco.cc/drugs/interferon-alfa/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Intravesical BCG](https://onco.cc/drugs/bcg-intravesical/), [Ivermectin](https://onco.cc/drugs/ivermectin/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [MK-1045](https://onco.cc/drugs/mk-1045/), [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/), [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/), [Olaparib](https://onco.cc/drugs/olaparib/), [Opevesostat](https://onco.cc/drugs/opevesostat/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [Peginterferon alfa-2b](https://onco.cc/drugs/peginterferon-alfa-2b/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [Selumetinib](https://onco.cc/drugs/selumetinib/), [Temozolomide](https://onco.cc/drugs/temozolomide/), [Vibostolimab](https://onco.cc/drugs/vibostolimab/), [Vorinostat](https://onco.cc/drugs/vorinostat/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/), [Harpoon Therapeutics](https://onco.cc/companies/harpoon-therapeutics/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [MSD Global Health Innovation Fund (Merck GHI)](https://onco.cc/companies/msd-global-health-innovation-fund/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)](https://onco.cc/trials/nct07489495/), [A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)](https://onco.cc/trials/nct07227402/), [A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)](https://onco.cc/trials/nct07190248/), [A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)](https://onco.cc/trials/nct07209111/), [A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)](https://onco.cc/trials/nct06997497/), [A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)](https://onco.cc/trials/nct07227597/), [A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)](https://onco.cc/trials/nct06925737/), [A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)](https://onco.cc/trials/nct06863272/), [A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)](https://onco.cc/trials/nct06833073/), [A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)](https://onco.cc/trials/nct06961006/), [A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)](https://onco.cc/trials/nct06305767/), [A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)](https://onco.cc/trials/nct05579132/), [A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)](https://onco.cc/trials/nct07519772/), [A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)](https://onco.cc/trials/nct07286149/), [A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)](https://onco.cc/trials/nct06428409/), [A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)](https://onco.cc/trials/nct07222488/), [A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)](https://onco.cc/trials/nct07060807/), [A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)](https://onco.cc/trials/nct06698042/), [A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)](https://onco.cc/trials/nct06843447/), [A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc](https://onco.cc/trials/nct07216703/), [A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)](https://onco.cc/trials/nct06637423/), [A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)](https://onco.cc/trials/nct06966700/), [A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)](https://onco.cc/trials/nct06890884/), [A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ](https://onco.cc/trials/nct07513376/), [A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)](https://onco.cc/trials/nct07554339/), [A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)](https://onco.cc/trials/nct07405151/), [A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)](https://onco.cc/trials/nct07634471/), [A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)](https://onco.cc/trials/nct07570173/), [A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)](https://onco.cc/trials/nct07318558/), [A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)](https://onco.cc/trials/nct07419295/), [A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)](https://onco.cc/trials/nct06163430/), [A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849](https://onco.cc/trials/nct05761223/), [A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).](https://onco.cc/trials/nct06307431/), [A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6](https://onco.cc/trials/nct05468697/), [A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)](https://onco.cc/trials/nct04489771/), [A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct04219254/), [A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)](https://onco.cc/trials/nct06345729/), [A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2](https://onco.cc/trials/nct04879329/), [A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)](https://onco.cc/trials/nct05845814/), [A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)](https://onco.cc/trials/nct06483334/), [A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct05669430/), [A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)](https://onco.cc/trials/nct07630974/), [A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)](https://onco.cc/trials/nct06644781/), [A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (](https://onco.cc/trials/nct06077760/), [A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)](https://onco.cc/trials/nct07221474/), [A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)](https://onco.cc/trials/nct06780085/), [A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)](https://onco.cc/trials/nct06979596/), [A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)](https://onco.cc/trials/nct03162536/), [A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).](https://onco.cc/trials/nct05947851/), [A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)](https://onco.cc/trials/nct05624554/), [A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)](https://onco.cc/trials/nct06136650/), [A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol](https://onco.cc/trials/nct06099782/), [A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)](https://onco.cc/trials/nct06941272/), [A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)](https://onco.cc/trials/nct06041802/), [A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study](https://onco.cc/trials/nct05899049/), [A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)](https://onco.cc/trials/nct02332668/), [A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)](https://onco.cc/trials/nct06623422/), [A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)](https://onco.cc/trials/nct07302347/), [A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34](https://onco.cc/trials/nct06731907/), [A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)](https://onco.cc/trials/nct06864169/), [A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)](https://onco.cc/trials/nct06660654/), [A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)](https://onco.cc/trials/nct06312176/), [A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)](https://onco.cc/trials/nct06841354/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)](https://onco.cc/trials/nct05722015/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension](https://onco.cc/trials/nct06212752/), [A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-](https://onco.cc/trials/nct05458297/), [A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)](https://onco.cc/trials/nct05406401/), [A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm](https://onco.cc/trials/nct06312137/), [A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan](https://onco.cc/trials/nct06952504/), [A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With](https://onco.cc/trials/nct06459180/), [A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)](https://onco.cc/trials/nct04225117/), [A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)](https://onco.cc/trials/nct05319730/), [A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)](https://onco.cc/trials/nct06356311/), [A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)](https://onco.cc/trials/nct06351631/), [A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)](https://onco.cc/trials/nct06330064/), [A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl](https://onco.cc/trials/nct06824467/), [A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv](https://onco.cc/trials/nct06780137/), [A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)](https://onco.cc/trials/nct06818643/), [A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.](https://onco.cc/trials/nct06116136/), [A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi](https://onco.cc/trials/nct06717347/), [A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)](https://onco.cc/trials/nct05562830/), [ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07158918/), [ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05405595/), [ASCENT-04 / KEYNOTE-D19](https://onco.cc/trials/ascent-04/), [BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07469774/), [BELLWAVE-011](https://onco.cc/trials/bellwave-011/), [Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL](https://onco.cc/trials/nct04924075/), [c-TRAK TN](https://onco.cc/trials/c-trak-tn/), [Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2](https://onco.cc/trials/nct05911295/), [EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma](https://onco.cc/trials/nct06556563/), [Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)](https://onco.cc/trials/nct04728893/), [Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)](https://onco.cc/trials/nct03742895/), [Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)](https://onco.cc/trials/nct03711032/), [Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)](https://onco.cc/trials/nct04241185/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ](https://onco.cc/trials/nct04895722/), [Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)](https://onco.cc/trials/nct07405164/), [GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab](https://onco.cc/trials/nct04652076/), [Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)](https://onco.cc/trials/nct05318469/), [KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)](https://onco.cc/trials/nct04165070/), [KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)](https://onco.cc/trials/nct07252739/), [KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)](https://onco.cc/trials/nct07232602/), [KEYNOTE-006](https://onco.cc/trials/keynote-006/), [KEYNOTE-010](https://onco.cc/trials/keynote-010/), [KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)](https://onco.cc/trials/keynote-017/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [KEYNOTE-048](https://onco.cc/trials/keynote-048/), [KEYNOTE-057](https://onco.cc/trials/keynote-057/), [KEYNOTE-062](https://onco.cc/trials/keynote-062/), [KEYNOTE-091 (PEARLS)](https://onco.cc/trials/keynote-091/), [KEYNOTE-119](https://onco.cc/trials/keynote-119/), [KEYNOTE-158](https://onco.cc/trials/keynote-158/), [KEYNOTE-170](https://onco.cc/trials/keynote-170/), [KEYNOTE-177](https://onco.cc/trials/keynote-177/), [KEYNOTE-204](https://onco.cc/trials/keynote-204/), [KEYNOTE-355](https://onco.cc/trials/keynote-355/), [KEYNOTE-407](https://onco.cc/trials/keynote-407/), [KEYNOTE-412](https://onco.cc/trials/keynote-412/), [KEYNOTE-426](https://onco.cc/trials/keynote-426/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [KEYNOTE-564](https://onco.cc/trials/keynote-564/), [KEYNOTE-590](https://onco.cc/trials/keynote-590/), [KEYNOTE-629](https://onco.cc/trials/keynote-629/), [KEYNOTE-641](https://onco.cc/trials/keynote-641/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [KEYNOTE-689](https://onco.cc/trials/keynote-689/), [KEYNOTE-716](https://onco.cc/trials/keynote-716/), [KEYNOTE-811](https://onco.cc/trials/keynote-811/), [KEYNOTE-826](https://onco.cc/trials/keynote-826/), [KEYNOTE-859](https://onco.cc/trials/keynote-859/), [KEYNOTE-921](https://onco.cc/trials/keynote-921/), [KEYNOTE-966](https://onco.cc/trials/keynote-966/), [KEYNOTE-991](https://onco.cc/trials/keynote-991/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/), [LITESPARK-005](https://onco.cc/trials/litespark-005/), [LITESPARK-011](https://onco.cc/trials/nct04586231/), [LITESPARK-012](https://onco.cc/trials/litespark-012/), [LITESPARK-022](https://onco.cc/trials/litespark-022/), [Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb](https://onco.cc/trials/nct03486873/), [MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)](https://onco.cc/trials/nct07431827/), [NeoPACT](https://onco.cc/trials/neopact/), [Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors](https://onco.cc/trials/nct04041310/), [Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy](https://onco.cc/trials/nct01874353/), [Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)](https://onco.cc/trials/nct06788912/), [Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)](https://onco.cc/trials/nct04976634/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)](https://onco.cc/trials/nct05224141/), [Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors](https://onco.cc/trials/nct06795412/), [Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-](https://onco.cc/trials/nct04624204/), [S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05101070/), [Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P](https://onco.cc/trials/nct06170788/), [Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)](https://onco.cc/trials/nct06132958/), [Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)](https://onco.cc/trials/nct06393374/), [Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct06074588/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)](https://onco.cc/trials/nct03407144/), [Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06016920/), [Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)](https://onco.cc/trials/nct04938817/), [SARC028](https://onco.cc/trials/sarc028/), [Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab](https://onco.cc/trials/nct04130516/), [Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)](https://onco.cc/trials/nct06428396/), [Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors](https://onco.cc/trials/nct04145622/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)](https://onco.cc/trials/nct06136624/), [Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)](https://onco.cc/trials/nct06596694/), [Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)](https://onco.cc/trials/nct06797635/), [Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)](https://onco.cc/trials/nct06686394/), [Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)](https://onco.cc/trials/nct02861573/), [Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)](https://onco.cc/trials/nct04634877/), [Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)](https://onco.cc/trials/nct05609968/), [Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)](https://onco.cc/trials/nct04895358/), [Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan](https://onco.cc/trials/nct04956692/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)](https://onco.cc/trials/nct05239741/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)](https://onco.cc/trials/nct05173987/), [Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)](https://onco.cc/trials/nct02362594/), [Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)](https://onco.cc/trials/nct03725059/), [Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)](https://onco.cc/trials/nct04380636/), [Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct06731478/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/), [Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)](https://onco.cc/trials/nct06353386/), [Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)](https://onco.cc/trials/nct06395103/), [Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)](https://onco.cc/trials/nct06780098/), [Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)](https://onco.cc/trials/nct04626479/), [Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)](https://onco.cc/trials/nct04626518/), [Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (](https://onco.cc/trials/nct07049926/), [Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)](https://onco.cc/trials/nct06469944/), [Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)](https://onco.cc/trials/nct06445972/), [Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)](https://onco.cc/trials/nct06780111/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/), [waveLINE-003](https://onco.cc/trials/waveline-003/)
- cancers: [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Gestational trophoblastic neoplasia](https://onco.cc/cancers/gestational-trophoblastic/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Pheochromocytoma and paraganglioma (PPGL)](https://onco.cc/cancers/pheochromocytoma-paraganglioma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- key papers: [Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial](https://onco.cc/key-papers/paper-litespark-011-motzer-lancet-2026/), [CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer](https://onco.cc/key-papers/paper-clear-nejm-2021/), [EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer](https://onco.cc/key-papers/paper-ev-302-nejm-2024/), [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/), [KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off](https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/), [KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma](https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/), [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer](https://onco.cc/key-papers/paper-keynote-048-lancet-2019/), [KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer](https://onco.cc/key-papers/paper-keynote-177-nejm-2020/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery](https://onco.cc/key-papers/paper-keynote-564-nejm-2021/), [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)](https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)](https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/), [Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ](https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/), [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer](https://onco.cc/key-papers/paper-olympia-overall-survival-ann-oncol-2022/), [PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours](https://onco.cc/key-papers/paper-paola-1-nejm-2019/), [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/), [Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial](https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/), [Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)](https://onco.cc/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- technologies: [BCG manufacturing and the bladder cancer BCG shortage](https://onco.cc/technologies/bcg-vaccine-manufacturing/), [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- bottlenecks: [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- institutions: [Harold C. Simmons Comprehensive Cancer Center, UT Southwestern](https://onco.cc/institutions/utsw-simmons/)

---
JSON: https://onco.cc/api/v1/entities/merck.json